Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT03961945
- Status
- Recruiting
Conditions
- Barrett Esophagus
- Esophageal Adenocarcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Accepted
Interventions
- Sponge Capsule — DEVICESubjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
Study Details
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
Key Dates
- Start date
- Jul 1, 2021
- Status verified
- Jan 2026
- Primary completion
- Jul 30, 2030
- Completion
- Jul 30, 2030
Study Design
- Enrollment
- 1,550 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- DIAGNOSTIC
Arms
- Other: Screening PopulationThose that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.
- Other: Upper endoscopy - Barrett's EsophagusThose that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
- Other: Upper endoscopy - No Barrett's EsophagusThose that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.
Primary Outcome Measure
Aim 1 - Screening Population [ Time Frame: 5 years ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | - |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | - |
| Mayo Clinic Health Systems - Austin | Austin | Minnesota | 55912 | Eduardo Antpack, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health Systems - Mankato | Mankato | Minnesota | 56001 | - |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | Prasad G. Iyer, M.D. (PRINCIPAL_INVESTIGATOR) |
| Northwell Health | New Hyde Park | New York | 11040 | - |
| Baylor Scott & White Research Institute | Dallas | Texas | 75246 | - |
| Mayo Clinic Health System-Eau Claire | Eau Claire | Wisconsin | 54701 | |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | 54601 | - |
Find similar trials in Scottsdale, AZ
Related Studies
- The Johns Hopkins Heartburn Center RegistryEnrolling By Invitation · Johns Hopkins University · Orange, California
- Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric AdenocarcinomaPHASE2 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
- Clinical Utility of WATS3D: A 5-Year Prospective StudyRecruiting · CDx Diagnostics · Bethpage, New York
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska